Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — Shareholder Meeting (November 2022)
22 slides from Lumos Diagnostics's shareholder meeting presentation, Nov 30, 2022
Slide 1: Chair's Address - Annual General Meeting
For personal use only ASX ANNOUNCEMENT Lumos Diagnostics Annual General Meeting Chair’s Address MELBOURNE, Australia (30 November 2022) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid point-of-care (POC) diagnostic technologies,today releases the Chairs’ Address for the
Slide 2: Chair's Address (continued)
Second, while we did not manage to achieve everything we were hoping to achieve with our own point-of-care diagnostic products, we did show meaningful progress with regulatory clearances for FebriDx in Brazil and the United Arab Emirates, and Interim Order authorisations for both ViraDx and CoviDx i
Slide 3: Chair's Address (continued) and About Lumos Diagnostics
still has available. As a result of our restructuring and reorganisation, we have reduced our underlying, operating cash burn to around US$1 million month and expect this to continue to decline as our commercial revenues grow. I believe that we have ‘right-sized’ the Company with the people, IP, cap
Slide 4: Media and Investor Contacts
Media Contacts: Matthew Wright – Australia Director, NWR Communications matt@nwrcommunications.com.au For personal use only +61 (0) 451 896 420 Investor Contact: Matthijs Smith – Lumos Diagnostics ir@lumosdiagnostics.com +61 3 9087 1598 Company Registered Office: Lumos Diagnostics Holdings Ltd Level
Slide 5: Lumos Diagnostics Holdings Limited Annual General Meeting
For personal use only Lumos Diagnostics Holdings Limited Annual General Meeting November 2022 www.lumosdiagnostics.com Confidential. This document and supporting materials contain confidential and proprietary business information from Lumos. 1
Slide 6: Disclaimer and Important Information
Disclaimer and Important Information For personal use only This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company). The information contained in this document (“Document”) has been prepared by Lumos Diagnostics Holdings Lim
Slide 7: Board of Directors
BOARD OF DIRECTORS For personal use only Sam Lanyon Bronwyn Le Grice Lawrence Mehren Catherine Robson Executive Chair Non-Executive Non-Executive Non-Executive Director Director Director 3
Slide 8: Format of Meeting
FORMAT OF MEETING For personal use only 1. Chair address 2. CEO address 3. General Questions 4. Q&A/Voting Procedure 5. Formal business of the shareholder meeting to consider and vote on the proposed resolutions as set out in the Notice of Meeting 6. Questions/Close 4
Slide 9: CEO Address
For personal use only CEO ADDRESS 5 © Lumos Diagnostics, all rights reserved Confidential 5
Slide 10: FY22 At A Glance
FY22 At A Glance For personal use only “ Having come from a long US$11.6 million total revenue in FY22 38% decrease vs FY21 career in the diagnostics industry, I joined Lumos with a US$9.4 million Commercial Services business unit revenue in FY22 45% decrease vs FY21 deep understanding of the needs
Slide 11: Commercial Services - FY22 Operational Summary
Commercial Services - FY22 Operational Summary For personal use only • Lumos commercial services revenue of US$9.4 million (v US$17.1 million FY21) - normalisation to pre-pandemic growth profile (US$5.3 million in FY20). • Provided development services on 11 active customer projects during FY22. • T
Slide 12: Lumos-branded Product Business - FY22 Summary
Lumos-branded Product Business - FY22 Summary For personal use only BACTERIAL VS VIRAL INFECTION 3-IN-1 COVID-19/FLU A/FLU B TEST SARS-COV-2 RAPID ANTIGEN TEST • Regulatory clearances for FebriDx in • Validation and verification work for • Interim Order (IO) authorization Brazil and UAE. the 3-ViraD
Slide 13: Cost Reduction Program—Restructure and Rationalization
Cost Reduction Program—Restructure and Rationalization For personal use only All numbers in USD • Ongoing cost reduction and management program initiated in April to reduce costs and monthly cash usage • Headcount now reduced from around 135 to 54 FTEs • Consolidated operations in Carlsbad, CA with
Slide 14: Revenue & Gross Profit
Revenue & Gross Profit For personal use only (US$ in thousands) REVENUE REVENUE MIX GROSS PROFIT $18,832 100% $20,000 $10,000 $8,751 50% CAGR 52% 80% $8,000 40% $15,000 $11,630 60% $6,000 30% $10,000 $4,456 $5,637 40% $4,000 20% $4,566 $5,000 $2,076 $2,444 $2,175 20% $2,000 10% $951 $0 0% $0 0% FY18
Slide 15: OPEX & EBITDA
OPEX & EBITDA For personal use only (US$ in thousands) OPERATING EXPENSES1 EBITDA2 NPAT3 FY20 FY21 FY22 $0 Underlying EBITDA -$ 18,250 $25,000 $22,706 Dep'n & Amortisation -$ 2,823 $19,198 $20,000 Impairements: -$5,000 Plant & Equipment -$ 3,801 $15,000 Intangibles -$ 12,562 $10,707 $10,000 -$10,000
Slide 16: The Opportunity For Lumos
The Opportunity For Lumos For personal use only Doug Ward – extensive experience in diagnostics industry • >30-year career in Diagnostics and Life Sciences industries • Roles with Roche/Ventana Medical, GE, Siemens, Bayer, Chiron, PGDX and Hologic which included: - Expansion of Ventana’s companion d
Slide 17: Industry Structure and Key Trends
Industry Structure and Key Trends For personal use only STRONG CATEGORY GROWTH GLOBAL POC DIAGNOSTIC TEST SALES • Significant growth anticipated from growing role of diagnostic tests in healthcare (US$ in billions) US$50B • Rapid, point-of-care tests increasingly being used – common in US settings 5
Slide 18: Lumos creates and manufactures new POC diagnostic tests
Lumos creates and manufactures new POC diagnostic tests For personal use only Strategic Innovation, Product Development Validation & Concept & Design & Transfer to Manufacturing Commercial Manufacturing • Product profiling • Reader/assay optimisation • Clinical verification • Commercial evaluation •
Slide 19: Lumos has a compelling and highly competitive offering
Lumos has a compelling and highly competitive offering For personal use only 1. Fully-integrated—from design to manufacturing 2. Proprietary reader platform for use in different settings Strategic Product Commercial Innovation Development Manufacturing Single-use Multi-use disposable Desktop readers
Slide 20: Lumos Business Model
Lumos Business Model For personal use only Lumos Commercial Customers Design Develop Manufacture Product concepts Contract Fees Margin from Sales & license payments from Services Manufacturing from own products 16
Slide 21: Promising Outlook
Promising Outlook For personal use only “ I believe we are entering the new financial year in a stronger Expand and diversify pipeline of commercial services projects position, as a much more focused and streamlined company. Continue to build foundation for long-term growth through strategic partner
Slide 22: www.lumosdiagnostics.com
For personal use only www.lumosdiagnostics.com 18
Lumos Diagnostics Holdings — Shareholder Meeting (November 2022) on 6ix